Clinical parameter | ATF (n = 20) | Placebo (n = 20) | p-value (inter-group differences) | |
---|---|---|---|---|
Primary outcome: | ||||
MSBI | Baseline | 62.8 ± 17.1 | 59.2 ± 14.8 | 0.529 |
Reevaluation | 45.2 ± 18.9 | 51.6 ± 19.5 | 0.383 | |
p-value (intra-group differences) | 0.001 | 0.018 | ||
Reduction | 17.6 ± 13.8 | 7.6 ± 11.3 | 0.035 | |
Secondary outcome: | ||||
PI | Baseline | 0.7 ± 0.5 | 0.7 ± 0.4 | 0.640 |
Reevaluation | 0.8 ± 0.5 | 0.7 ± 0.4 | 0.445 | |
p-value (intra-group differences) | 0.17 | 0.34 | ||
Reduction | 0.09 ± 0.27 | 0.06 ± 0.26 | 0.947 | |
API | Baseline | 52.2 ± 19.1 | 43.3 ± 14.7 | 0.157 |
Reevaluation | 57.3 ± 20.8 | 45.1 ± 15.9 | 0.056 | |
p-value (intra-group differences) | 0.177 | 0.602 | ||
Reduction | 5.1 ± 14.9 | 1.8 ± 12.0 | 0.495 |